Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood‐based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 3×
“Based on research from the past several decades andmore recent data from larger observational studies such as ADNI, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), and DIAN, a consensus is emerging that AD begins decades before dementia onset [5,33] and is heralded by successive changes in m…”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“[4], in which a gradual, ordered, and successive alteration in AD biomarkers, beginning with amyloid pathology, then tauopathy, and later neurodegeneration, preceding clinical symptoms, and eventual dementia, recapitulates the key tenets of the amyloid cascade hypothesis [54,55].”
BackgroundCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“The presumption that these biomarker effects represented a clinically relevant treatment effect, however, was called into question when no clinical benefit was found in the phase III trials, despite hints that biomarkers were impacted by therapy [19].”
BackgroundSelf-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Other available biomarkers that reflect pathogenic processes of the disease include CSF levels of total tau (T-tau) and P-tau, which are related to cortical axonal degeneration and tangle pathology [41,42]; CSF Ab42 and amyloid PET imaging, which correlate negatively and positively, respectively, with amyloid plaque l…”
BackgroundProfound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“This has now radically changed as clinical trials move toward earlier stages of AD, before extensive neurodegeneration has occurred [7–9], and even to secondary prevention before symptom onset [10–12], when disease-modifying treatments are likely to have maximal effect.”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 1×
“The Centiloid Project proposes to calibrate all amyloid imaging tracers according to a unified and standardized numerical scale [52] and would theoretically allow results from studies using different tracers to be combined and compared.”
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Self-citationImmunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 1×
“Novel imaging biomarkers, including tau imaging [63–67], advanced MRI methodologies [68,69], and new neuropsychological testing protocols, have also shown promise in providing a more comprehensive picture of the progression of dementing diseases [70–73].”
BackgroundNeuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · cited 1×
“This has now radically changed as clinical trials move toward earlier stages of AD, before extensive neurodegeneration has occurred [7–9], and even to secondary prevention before symptom onset [10–12], when disease-modifying treatments are likely to have maximal effect.”
BackgroundSelf-citationPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 2×
“Although recent data support many aspects of this model [2,16,26,56–58], some do not and the model has been updated accordingly [34].”
BackgroundResultYKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · cited 1×
“developing cerebrospinal fluid (CSF) and imaging biomarkers has shown that AD brain changes can be detected and used for diagnosis and prognosis of AD [2,3].”
BackgroundSelf-citationEffectiveness of regional DTI measures in distinguishing Alzheimer’s disease, MCI, and normal aging
Nir, T. M., Jahanshad, N., Villalon-Reina, J. E., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.07.006 · Cited by 348 · cited 1×
“Novel imaging biomarkers, including tau imaging [63–67], advanced MRI methodologies [68,69], and new neuropsychological testing protocols, have also shown promise in providing a more comprehensive picture of the progression of dementing diseases [70–73].”
BackgroundCSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234 · cited 1×
“The phase III bapineuzumab trial, in particular, went forward in part based on findings in phase II studies that showed modest reductions in brain amyloid [17], and CSF phosphorylated tau (P-tau) concentrations [18].”
BackgroundDeveloping novel blood‐based biomarkers for Alzheimer's disease
Snyder, H. M., Carrillo, M. C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., Mielke, M. M., O'Bryant, S., Sarasa, M., Sj⊘gren, M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.007 · Cited by 177
Self-citationAntiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126 · cited 1×
“One contributing factor is that some of the enrolled trial subjects may not have AD [21].”
BackgroundAlliance for aging research AD biomarkers work group: structural MRI
Jack, C. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.011 · Cited by 64 · cited 1×
“astrocytes, microglia), inflammatory processes, and associated alterations of interstitial fluid volume [37,40].”
Background
Cited by
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
“Biomarkers that capture biological processes in AD are increasingly used to support the diagnosis of AD in research, drug development, and clinical practice.(1) The most wellestablished AD biomarkers include structural magnetic resonance imaging (MRI); cerebrospinal fluid (CSF) biomarkers of Aβ, tau, and neuronal inju…”
Self-citationHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Self-citationRabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
Self-citationAlzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Metadata
- Authors
- Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. S., Bateman, R. J., Bain, L. J., & Liu, E.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-10-02
- Volume
- 1
- Issue
- 4
- Pages
- 412-419
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2151013350
- Cited by
- 102
- References
- 35
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.